Abstract

Spontaneous reporting of possible adverse effects of drugs can make an important contribution to their early detection, but is of limited value for estimation of incidence. At present, the enormous differences between countries in the organization and functioning of spontaneous reporting systems limit their potential. International standardization and coordination of procedures would be easy and highly beneficial. Health professionals in all countries should be encouraged and appropriately motivated to report important adverse drug experiences to the appropriate recipient in their country. The pharmaceutical manufacturer in the reporting country should be charged with the investigation of all ADR reports concerning their drugs, regardless of who is the initial recipient of the report. The reporting of investigated ADRs by pharmaceutical manufacturers to their national drug authorities should be strengthened and standardized internationally. Free exchange of information concerning ADRs should be establishe...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.